NCT06891703RecruitingPhase 1
Phase 1 study to evaluate [18F]ACI-15916 as a potential PET radioligand for imaging α-synuclein deposits in the brain of patients with suspected α-synuclein pathology compared with healthy volunteers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 25 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- First submitted
- 31 Oct 2024
- Start date
- 4 Mar 2025
- Lead sponsor
- AC Immune S.A.
- Diseases
- Lewy body dementia, Parkinson disease
- EU CT number
- 2024-515664-31-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 46
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Coordinator of this site? Confirm its status | Solna | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.